Emmaus Life Sciences (NASDAQ:EMMA) CEO Yutaka Niihara acquired 32,499 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were bought at an average cost of $4.03 per share, with a total value of $130,970.97. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Yutaka Niihara also recently made the following trade(s):
- On Thursday, August 29th, Yutaka Niihara purchased 20,000 shares of Emmaus Life Sciences stock. The stock was purchased at an average price of $3.19 per share, with a total value of $63,800.00.
- On Tuesday, August 27th, Yutaka Niihara bought 31,700 shares of Emmaus Life Sciences stock. The shares were bought at an average price of $2.76 per share, with a total value of $87,492.00.
- On Wednesday, August 21st, Yutaka Niihara bought 19,500 shares of Emmaus Life Sciences stock. The shares were bought at an average price of $3.38 per share, with a total value of $65,910.00.
Shares of NASDAQ:EMMA opened at $2.77 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.44 and a quick ratio of 1.44. Emmaus Life Sciences has a fifty-two week low of $2.49 and a fifty-two week high of $14.70. The firm has a market cap of $131.48 million, a P/E ratio of -0.25 and a beta of 2.91.
Separately, Zacks Investment Research upgraded shares of Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research report on Tuesday, July 30th.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.
Featured Story: Understanding Relative Strength Index
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.